<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inflarx N.v. — News on 6ix</title>
<link>https://6ix.com/company/inflarx-nv</link>
<description>Latest news and press releases for Inflarx N.v. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inflarx-nv" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835824878dffbe2df0fc347.webp</url>
<title>Inflarx N.v.</title>
<link>https://6ix.com/company/inflarx-nv</link>
</image>
<item>
<title>InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-reports-new-mechanistic-data-for-izicopan-supporting-its-potential-as-a-best-in-class-c5ar-inhibitor</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-reports-new-mechanistic-data-for-izicopan-supporting-its-potential-as-a-best-in-class-c5ar-inhibitor</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by</description>
</item>
<item>
<title>InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium</guid>
<pubDate>Tue, 31 Mar 2026 11:30:00 GMT</pubDate>
<description>JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation SymposiumApril 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pi</description>
</item>
<item>
<title>InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-highlights-clinical-activity-of-vilobelimab-in-pyoderma-gangrenosum-in-late-breaker-oral-presentation-at-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-highlights-clinical-activity-of-vilobelimab-in-pyoderma-gangrenosum-in-late-breaker-oral-presentation-at-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Mon, 30 Mar 2026 11:30:00 GMT</pubDate>
<description>Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum (PG) were featured in an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held March 27-31, 2026, in Denver, CO. The data presented incl</description>
</item>
<item>
<title>InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-reports-full-year-2025-results-and-highlights-key-achievements-and-expected-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-reports-full-year-2025-results-and-highlights-key-achievements-and-expected-milestones</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of</description>
</item>
<item>
<title>InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-late-breaker-oral-presentation-on-vilobelimab-phase-3-results-in-pyoderma-gangrenosum-at-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-late-breaker-oral-presentation-on-vilobelimab-phase-3-results-in-pyoderma-gangrenosum-at-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by</description>
</item>
<item>
<title>InflaRx to Report Full Year 2025 Results on March 19, 2026</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-to-report-full-year-2025-results-on-march-19-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-to-report-full-year-2025-results-on-march-19-2026-2</guid>
<pubDate>Thu, 12 Mar 2026 11:30:00 GMT</pubDate>
<description>JENA, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2025 on March 19, 2026, before the market opens. No conference call is planned. About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by appl</description>
</item>
<item>
<title>InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-in-the-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-in-the-leerink-partners-global-healthcare-conference</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows: Leerink Partners Global Healthcare ConferenceMarch 8 - 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the</description>
</item>
<item>
<title>InflaRx Announces Participation in February Investor Conferences</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-february-investor-123000813</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-february-investor-123000813</guid>
<pubDate>Thu, 29 Jan 2026 12:30:00 GMT</pubDate>
<description>JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows: Guggenheim Securities Emerging Outlook: Biotech Summit 2026February 11 - 12, 2026 in New York, NYFireside chat on Wednesday, February 11 at 11:30 AM ET InflaRx will also conduct one-on-one investor meetings</description>
</item>
<item>
<title>InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-strategy-focused-capital-130000085</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-strategy-focused-capital-130000085</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographiesToward the goal of fast-tracking izicopan development across all applicable I&I indications, InflaR</description>
</item>
<item>
<title>InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-provides-phase-3-data-123000352</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-provides-phase-3-data-123000352</guid>
<pubDate>Tue, 30 Dec 2025 12:30:00 GMT</pubDate>
<description>While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effectInflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the Company anticipates would only be conducted in co</description>
</item>
<item>
<title>InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-international-nonproprietary-name-123000172</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-international-nonproprietary-name-123000172</guid>
<pubDate>Thu, 11 Dec 2025 12:30:00 GMT</pubDate>
<description>JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended International Nonpropriet</description>
</item>
<item>
<title>InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-reports-positive-phase-2a-123000125</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-reports-positive-phase-2a-123000125</guid>
<pubDate>Mon, 10 Nov 2025 12:30:00 GMT</pubDate>
<description>Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concernIn HS, over 4 weeks of therapy, InflaRx observed rapid and clinically meaningful reductions in abscesses and nodules (ANs) and draining tunnels (dTs), robust HiSCR responses that continued to deepen four weeks after the treatment period, with substantial reductions in patient reported pain scores, ove</description>
</item>
<item>
<title>InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announce-topline-data-phase-210500490</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announce-topline-data-phase-210500490</guid>
<pubDate>Fri, 07 Nov 2025 21:05:00 GMT</pubDate>
<description>Company expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CETCompany also expects to publish third quarter 2025 financial results on the same day pre-market JENA, Germany, Nov. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report topline data from the Phase 2a clinical trial of oral C5aR inhibi</description>
</item>
<item>
<title>InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-guggenheim-securities-112000891</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-guggenheim-securities-112000891</guid>
<pubDate>Tue, 21 Oct 2025 11:20:00 GMT</pubDate>
<description>JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. Details are as follows: Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceNovember 10 - 12, 2025 in Boston, MAFireside chat on November 11 at 2:30 PM ET InflaRx will also conduct one-on-one inv</description>
</item>
<item>
<title>InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-regains-compliance-nasdaq-minimum-123000117</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-regains-compliance-nasdaq-minimum-123000117</guid>
<pubDate>Fri, 12 Sep 2025 12:30:00 GMT</pubDate>
<description>JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated September 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth under Nasd</description>
</item>
<item>
<title>InflaRx Announces Participation in September Investor Conferences</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-september-investor-113000096</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-participation-september-investor-113000096</guid>
<pubDate>Thu, 21 Aug 2025 11:30:00 GMT</pubDate>
<description>JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows: Cantor Global Healthcare Conference 2025September 3 - 5, 2025 in New York, NYFireside chat on September 4th at 9:10 AM ET InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view</description>
</item>
<item>
<title>InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-reports-second-quarter-2025-113000055</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-reports-second-quarter-2025-113000055</guid>
<pubDate>Thu, 07 Aug 2025 11:30:00 GMT</pubDate>
<description>INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, with Staidson expecting Phase 3 study initiationInflaRx working diligently toward unblinding of stopped Phase 3 pyoderma gangrenosum (PG) trial so that all data can be analyzed later this yearEnrollme</description>
</item>
<item>
<title>InflaRx to Report Second Quarter 2025 Results on August 7, 2025</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-report-second-quarter-2025-113000537</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-report-second-quarter-2025-113000537</guid>
<pubDate>Thu, 31 Jul 2025 11:30:00 GMT</pubDate>
<description>JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary an</description>
</item>
<item>
<title>InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-receipt-nasdaq-deficiency-201500541</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-receipt-nasdaq-deficiency-201500541</guid>
<pubDate>Fri, 11 Jul 2025 20:15:00 GMT</pubDate>
<description>JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated July 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the mini</description>
</item>
<item>
<title>InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum</title>
<link>https://6ix.com/company/inflarx-nv/news/inflarx-announces-outcome-interim-analysis-053000204</link>
<guid isPermaLink="true">https://6ix.com/company/inflarx-nv/news/inflarx-announces-outcome-interim-analysis-053000204</guid>
<pubDate>Wed, 28 May 2025 05:30:00 GMT</pubDate>
<description>JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility. This recommendation was based on data analysis of the first 30 patients enrolled in t</description>
</item>
</channel>
</rss>